DAVID M VISOKEY DO
Prescription History 1912979261
Internal Medicine - Pulmonary Disease in Waterloo, IA

NPI Status: Active since February 02, 2006

Contact Information

2710 SAINT FRANCIS DR
SUITE 402
WATERLOO, IA
ZIP 50702
Phone: (319) 272-5000
Fax: (319) 272-5512

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAVID M VISOKEY DO, an active Pulmonary Disease specialist practicing in Waterloo, IA. Our medical registry currently tracks 40 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 3,911 documented patient claims. Among these therapy options, the most frequently utilized medication is Trelegy Ellipta, which accounts for 1,071 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 68
30-Day Fills 92.0
Days Supply 2,760
IA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply842
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 195.7% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,827.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$585.70

State Avg Cost Per Claim

$526.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
IA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.7
Peer Average Days Supply1,040
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,816.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$486.91

State Avg Cost Per Claim

$587.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 455
30-Day Fills 498.5
Days Supply 11,848
IA State Average Benchmarks
Peer Average Claims50.0
Peer Average 30-Day Fills58.3
Peer Average Days Supply1,323
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 810.0% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,012.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.60

State Avg Cost Per Claim

$47.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 169
30-Day Fills 196.0
Days Supply 5,880
IA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills39.9
Peer Average Days Supply1,181
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 397.1% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $94,928.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$561.71

State Avg Cost Per Claim

$544.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 63
30-Day Fills 66.0
Days Supply 1,980
IA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills29.5
Peer Average Days Supply880
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 162.5% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,554.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$278.64

State Avg Cost Per Claim

$286.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 29.2
Days Supply 350
IA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills34.9
Peer Average Days Supply366
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $229.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.20

State Avg Cost Per Claim

$10.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Bevespi Aerosphere

Generic Formulation: Glycopyrrolate/Formoterol FumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 1,050
IA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply806
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 45.8% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,811.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$451.76

State Avg Cost Per Claim

$480.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 2 medications: glycopyrrolate and formoterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. Glycopyrrolate/formoterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as formoterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 310
30-Day Fills 339.0
Days Supply 10,170
IA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills41.5
Peer Average Days Supply1,233
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 811.8% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $143,080.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$461.55

State Avg Cost Per Claim

$487.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 370
30-Day Fills 429.0
Days Supply 12,870
IA State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills48.4
Peer Average Days Supply1,448
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 781.0% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $281,293.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$760.25

State Avg Cost Per Claim

$732.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Cefdinir

Generic Formulation: CefdinirSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 106
IA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.2
Peer Average Days Supply218
Conservative Utilization

This provider writes prescriptions for this formulation 48.0% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $282.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.73

State Avg Cost Per Claim

$20.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A third-generation oral cephalosporin antibacterial agent that is used to treat bacterial infections of the respiratory tract and skin.

Therapeutic Applications

Cefdinir is used to treat a wide variety of bacterial infections. This medication is known as a cephalosporin antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 16.3
Days Supply 490
IA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills23.6
Peer Average Days Supply680
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,583.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$660.28

State Avg Cost Per Claim

$580.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dulera

Generic Formulation: Mometasone/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 28
30-Day Fills 28.0
Days Supply 840
IA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply560
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 75.0% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,278.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$367.08

State Avg Cost Per Claim

$394.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of mometasone furoate and formoterol fumarate that is used as an inhaled dosage form for the treatment of ASTHMA.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. It contains 2 medications: mometasone and formoterol. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 63
30-Day Fills 74.3
Days Supply 2,204
IA State Average Benchmarks
Peer Average Claims81.0
Peer Average 30-Day Fills115.0
Peer Average Days Supply3,166
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,950.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$681.75

State Avg Cost Per Claim

$720.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Fasenra Pen

Generic Formulation: BenralizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 31.9
Days Supply 952
IA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills35.8
Peer Average Days Supply1,067
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $108,476.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,026.50

State Avg Cost Per Claim

$5,477.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Benralizumab is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 18.0
Days Supply 540
IA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills28.1
Peer Average Days Supply841
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,290.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$480.92

State Avg Cost Per Claim

$404.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone Propionate

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
IA State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills65.9
Peer Average Days Supply1,968
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.3% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $182.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.23

State Avg Cost Per Claim

$15.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 31
30-Day Fills 63.0
Days Supply 1,890
IA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.3
Peer Average Days Supply818
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 47.6% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,686.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$344.72

State Avg Cost Per Claim

$253.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 80
30-Day Fills 90.0
Days Supply 2,700
IA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply920
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 207.7% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $33,939.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$424.25

State Avg Cost Per Claim

$443.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Ipratropium Bromide

Generic Formulation: Ipratropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 22.3
Days Supply 623
IA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills42.6
Peer Average Days Supply1,125
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.4% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $796.01 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.23

State Avg Cost Per Claim

$45.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Therapeutic Applications

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Modafinil

Generic Formulation: ModafinilSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 38
30-Day Fills 43.0
Days Supply 1,223
IA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply804
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 65.2% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,471.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$65.05

State Avg Cost Per Claim

$233.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.

Therapeutic Applications

Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness. Modafinil does not take the place of getting enough sleep. It should not be used to treat tiredness or hold off sleep in people who do not have a sleep disorder. It is not known how modafinil works to keep you awake. It is thought to work by affecting certain substances in the brain that control the sleep/wake cycle.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 64
30-Day Fills 114.0
Days Supply 3,412
IA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills112.6
Peer Average Days Supply3,341
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $745.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.65

State Avg Cost Per Claim

$15.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Pirfenidone

Generic Formulation: PirfenidoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
IA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.6
Peer Average Days Supply495
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,487.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,905.47

State Avg Cost Per Claim

$5,981.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pirfenidone is used to treat a certain lung disease called idiopathic pulmonary fibrosis (IPF). This disease causes the lungs to get scarred and become stiff, making it hard to breathe. Pirfenidone may help slow down the worsening of your IPF.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 277
30-Day Fills 314.6
Days Supply 7,251
IA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills54.3
Peer Average Days Supply923
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 502.2% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,367.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.94

State Avg Cost Per Claim

$5.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Pulmicort Flexhaler

Generic Formulation: BudesonideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 14.0
Days Supply 420
IA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills18.9
Peer Average Days Supply536
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,946.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$328.85

State Avg Cost Per Claim

$270.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.

Therapeutic Applications

Budesonide is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication belongs to a class of drugs known as corticosteroids. It works directly in the lungs to make breathing easier by reducing the irritation and swelling of the airways. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 24
30-Day Fills 39.0
Days Supply 1,170
IA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills24.3
Peer Average Days Supply725
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,903.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$162.63

State Avg Cost Per Claim

$373.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Serevent Diskus

Generic Formulation: Salmeterol XinafoateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 480
IA State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills14.4
Peer Average Days Supply431
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 33.3% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,338.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$458.67

State Avg Cost Per Claim

$520.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Salmeterol is used as a long-term (maintenance) treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It should only be used long-term if your asthma symptoms are not controlled by your other asthma medications (such as inhaled corticosteroids). Salmeterol must not be used alone to treat asthma. (See also Warning section.) It is also used to prevent asthma brought on by exercise (bronchospasm). Salmeterol works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication does not work right away and should not be used for sudden attacks of breathing trouble. Your doctor must prescribe a quick-relief medicine/inhaler (such as albuterol) for sudden shortness of breath/asthma attacks while you are on this medication. You should always have a quick-relief inhaler with you. Consult your doctor or pharmacist for more details. This medication should be used in combination with other medications such as long-acting inhaled corticosteroids. However, it should not be used with other long-acting inhaled beta agonists (such as formoterol, combination salmeterol/fluticasone) since this may increase your risk for side effects. It is recommended that children and teenagers, who need to use salmeterol to treat their asthma, should use a combination salmeterol/fluticasone product. Check with your child's doctor to see if this product is the right product for your child. In patients with asthma, this medication should not be used when breathing problems can be controlled with inhaled corticosteroids (such as flunisolide, fluticasone) and occasional

Sildenafil Citrate

Generic Formulation: Sildenafil CitrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply864
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $369.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.58

State Avg Cost Per Claim

$129.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.

Therapeutic Applications

Sildenafil is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise. This medication is not recommended for use in children. Discuss the risks and benefits of this medication with the doctor.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 101
30-Day Fills 114.0
Days Supply 3,420
IA State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills34.4
Peer Average Days Supply1,030
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 260.7% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,699.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$600.99

State Avg Cost Per Claim

$633.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 57
30-Day Fills 63.0
Days Supply 1,890
IA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills37.6
Peer Average Days Supply1,125
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 83.9% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31,414.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$551.12

State Avg Cost Per Claim

$581.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 17
30-Day Fills 20.5
Days Supply 576
IA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills27.5
Peer Average Days Supply409
Conservative Utilization

This provider writes prescriptions for this formulation 29.2% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $31.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$1.83

State Avg Cost Per Claim

$6.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Sunosi

Generic Formulation: Solriamfetol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 29
30-Day Fills 29.0
Days Supply 870
IA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.1
Peer Average Days Supply513
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.6% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,091.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$899.71

State Avg Cost Per Claim

$809.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to improve wakefulness in people that have too much daytime sleepiness due to certain sleep problems (narcolepsy, obstructive sleep apnea). It may work by changing the amounts of certain substances (dopamine, norepinephrine) in your body. This medication is not used to treat the cause of obstructive sleep apnea-OSA. Continue treatment for OSA, such as using continuous positive airway pressure (CPAP), while using this medication.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 185
30-Day Fills 213.0
Days Supply 6,390
IA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills40.7
Peer Average Days Supply1,218
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 478.1% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $86,479.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$467.46

State Avg Cost Per Claim

$483.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Theophylline Er

Generic Formulation: Theophylline AnhydrousSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
IA State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply774
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $994.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$90.39

State Avg Cost Per Claim

$214.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.

Therapeutic Applications

Theophylline is used to treat lung diseases such as asthma and COPD (bronchitis, emphysema). It must be used regularly to prevent wheezing and shortness of breath. This medication belongs to a class of drugs known as xanthines. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. It also decreases the lungs' response to irritants. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 1,071
30-Day Fills 1,218.0
Days Supply 36,540
IA State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills64.3
Peer Average Days Supply1,918
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,883.3% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $823,094.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$768.53

State Avg Cost Per Claim

$772.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Varenicline Tartrate

Generic Formulation: Varenicline TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 378
IA State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills16.8
Peer Average Days Supply460
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,848.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$296.03

State Avg Cost Per Claim

$389.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.

Therapeutic Applications

Varenicline is used by adults to help stop smoking. To increase your chance of success, use this medication with a stop-smoking program that includes education, support, and counseling. Quitting smoking lowers your risk of heart and lung disease, as well as cancer. Varenicline works by blocking nicotine's effects in the brain that make you want to smoke. Discuss the risks and benefits of this medication, as well as other ways to quit smoking (such as nicotine replacement treatment), with your doctor.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 115
30-Day Fills 123.4
Days Supply 2,770
IA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills28.9
Peer Average Days Supply645
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 342.3% higher than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,742.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$67.32

State Avg Cost Per Claim

$70.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 16.0
Days Supply 480
IA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills25.8
Peer Average Days Supply774
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,500.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$458.37

State Avg Cost Per Claim

$294.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 23.0
Days Supply 690
IA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills71.3
Peer Average Days Supply2,009
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.1% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,274.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$737.50

State Avg Cost Per Claim

$824.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Zolpidem Tartrate

Generic Formulation: Zolpidem TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 530
IA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills49.4
Peer Average Days Supply1,440
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.6% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $147.47 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.19

State Avg Cost Per Claim

$9.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.

Therapeutic Applications

Zolpidem is used for a short time to treat a certain sleep problem (insomnia) in adults. If you have trouble falling asleep, it helps you fall asleep faster, so you can get a better night's rest. Zolpidem belongs to a class of drugs called sedative-hypnotics. It acts on your brain to produce a calming effect.

Zolpidem Tartrate Er

Generic Formulation: Zolpidem TartrateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
IA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills18.7
Peer Average Days Supply528
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,768.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$147.34

State Avg Cost Per Claim

$50.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.

Therapeutic Applications

Zolpidem is used for a short time to treat a certain sleep problem (insomnia) in adults. If you have trouble falling asleep, it helps you fall asleep faster, so you can get a better night's rest. Zolpidem belongs to a class of drugs called sedative-hypnotics. It acts on your brain to produce a calming effect.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DAVID M VISOKEY DO provides transparency into local medical care patterns within Waterloo, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.